CN102973722A

CN102973722A - Novel anesthetic

Info

Publication number: CN102973722A
Application number: CN2012105443007A
Authority: CN
Inventors: 赵作君; 周洁萍
Original assignee: 赵作君
Current assignee: Bengbu Hangyu Intellectual Property Service Co., Ltd
Priority date: 2012-11-28
Filing date: 2012-11-28
Publication date: 2013-03-20
Anticipated expiration: 2032-11-28
Also published as: CN102973722B

Abstract

The invention provides a novel anesthetic, which comprises the following components in percentage by weight: 85 to 90 percent of propofol, 4 to 8 percent of datura flower extract, 0.5 to 1 percent of mentholum, 0.5 to 2.5 percent of chamomile, 1 to 3 percent of pseudo-ginseng powder, and 1 to 3 percent of astragalus powder. According to the novel anesthetic, the principle of combining traditional Chinese and western medicine is adopted, the original propofol drug effect can be maintained by propofol serving as a basic drug, datura flower serving as an auxiliary drug, mentholum and chamomile with pain relieving effect, astragalus with blood pressure dual-direction regulating effect and antitetanic pseudo-ginseng, the function of analgesia is increased, and the problem of local side effect caused by local pains when the propofol is used for injecting can be solved; adverse responses of myoclonus, nausea, emesis, respiratory depression which easily occurs and the like happening to partial patients in anaesthesia recovering period can be solved; and the dosage of propofol can be reduced, and the safety is increased.

Description

The Novel anesthesia agent

Technical field

The present invention relates to a kind of anesthetis, be specifically related to a kind of Novel anesthesia agent that contains propofol and Chinese medicine composition.

Background technology

Anesthesia be when performing a surgical operation or be eliminate pain when carrying out the diagnostic test operation, ensure patient safety, create the whole bag of tricks that good surgical condition is taked, mainly comprise general anesthesia, local anesthesia and combined anesthesia.Wherein general anesthesia refers to suck or the intravenous injection anaesthetic from respiratory tract, the state that reversibility loss of consciousness, analgesis occur, propofol is a kind of anesthetis that often adopts clinically at present, propofol is a kind ofly to induce and keep anaesthetizing and calm intravenous anesthesia agent, and propofol has rapid induction anesthesia and fast from the performance of anesthesia recovery.

Although the Comparison of propofol is good, but in using the propofol process, the phenomenon that local pain, Blood pressure drop and transience respiratory arrest when injection, occur, sometimes also can cause patient's myoclonus, incidence rate is about 1%, between the anesthesia of patient Resuscitation Period, occur feeling sick, vomit and the headache phenomenon, the propofol agent does not have the pain relieving performance in addition, need be used analgesic drug product in anaesthesia process, alleviates pain.

Summary of the invention

The present invention is directed to above-mentioned the deficiencies in the prior art, a kind of Novel anesthesia agent is provided, this Novel anesthesia agent not only has the performance of propofol, also has the analgesia function, and has solved the use propofol when injection, the local side effects of local pain occurs; Solved the part patient occurs between the anesthesia Resuscitation Period myoclonus, felt sick, vomiting and the untoward reaction such as respiration inhibition easily occurs; Reduce the using dosage of propofol, improved safety.

Anesthetis of the present invention mainly is comprised of propofol, and solving the technical scheme that its technical problem adopts is also to comprise Flos Daturae extract, Mentholum, camomile extract, Radix Notoginseng powder and astragalus membranaceus powder, and concrete weight content proportioning is propofol 85～90%; Flos Daturae extract 4%～8%; Mentholum 0.5%～1%; Camomile extract 0.5%～2.5%; Radix Notoginseng powder 1%～3%; Astragalus membranaceus powder 1%～3%.

Novel anesthesia agent preparation process of the present invention is as follows:

Flos Daturae extract, Mentholum, camomile extract, Radix Notoginseng powder and astragalus membranaceus powder according to prescription dosage, are joined in the propofol emulsion, and mix and blend under 20～25 ℃ of temperature evenly mixes and leaves standstill, and uses the 20ml vial to seal up for safekeeping.

The using method of Novel anesthesia agent of the present invention:

Novel anesthesia agent of the present invention can be assisted for spinal cord and epidural anesthesia, and is used with premedicant, neuromuscular blocking drug, inhalation anesthetic and the analgesic commonly used; But short and small operation need not used analgesic, cooperates low dose of analgesic as general anesthesia, has reduced the side effect that other analgesic using dosages bring.Suggestion uses target control pump or micro pump to carry out intravenous injection.Novel anesthesia agent of the present invention also can be diluted rear use, can only dilute with 5% glucose intravenous fluid, and dilution factor must not surpass 1: 5 (1.5mg/ml).Adult's dosage is 0.5～1.5mg/kg (induction period), and injection speed is controlled at 2mg/ second (induction period), 2～6mg/kg/h (maintenance phase); The pediatric pharmaceuticals amount is 1.0～2.0mg/kg (induction period), and injection speed is controlled at 2mg/ second (induction period), 5～8mg/kg/h (maintenance phase).

In the anesthetis of the present invention prescription: 1, Flos Daturae, contain alkaloid and atropine, have the effect that narcotic analgesic, spasmolytic are only jerked.2, Mentholum, having stimulates the skin permeation mucosa, the function of antipruritic, antiinflammatory, pain relieving.3, Flos Matricariae chamomillae can alleviate anxiety, anxiety, indignation and frightened, and the people is loosened; The function that has simultaneously pain relieving.Can relax myalgia, especially because of the nervous pain that causes.4, Radix Notoginseng, contain Radix Notoginseng total arasaponins, smooth muscle is had calm effect, can loosen overwrought muscle, make it reach sufficient rest, have the effect that antiallergic, anti-tic, emesis, anti-inflammatory, antipruritic, rheumatism, antibiotic, spasmolytic, promotion scab.5, the Radix Astragali contains flavone and Saponin constituents, has cardiotonic, and the heart contraction amplitude is increased, and output increases, and is more obvious to the effect of poisoning or tired failure heart; Also have the adjusting blood pressure, blood pressure is had certain dual regulation, but blood pressure lowering, and when blood pressure was down to the shock level, the Radix Astragali can make again blood pressure slightly rise and keep stable.

The invention has the beneficial effects as follows: adopt combination of Chinese and Western medicine principle, take propofol as basic medicine, Flos Daturae is ancillary drug, and be equipped with Mentholum and the Flos Matricariae chamomillae of analgesic effect, have astragalus membranaceus powder and the antitetanic Radix Notoginseng powder of blood pressure dual regulation, thereby not only keep original propofol drug effect, also increased and have the analgesia function, and solved the use propofol when injection, the local side effects of local pain occurred; Solved the part patient occurs between the anesthesia Resuscitation Period myoclonus, felt sick, vomiting and the untoward reaction such as respiration inhibition easily occurs; Reduce the using dosage of propofol, improved safety.

The specific embodiment

Example 1

A kind of Novel anesthesia agent mainly is comprised of propofol, also comprises Flos Daturae extract, Mentholum, camomile extract, Radix Notoginseng powder, Ramulus Cinnamomi powder and astragalus membranaceus powder, and concrete weight content proportioning is propofol 88%; Flos Daturae extract 6%; Mentholum 0.7%; Camomile extract 1.5%; Radix Notoginseng powder 1.8%; Astragalus membranaceus powder 2.0%.

With Flos Daturae extract, Mentholum, camomile extract, Radix Notoginseng powder and astragalus membranaceus powder according to the prescription dosage, join in the propofol emulsion, mix and blend under 20～25 ℃ of temperature evenly mixes and leaves standstill, strict with after the national relevant specification processing again, use the 20ml vial to seal up for safekeeping.

Novel anesthesia agent of the present invention can be assisted for spinal cord and epidural anesthesia, and is used with premedicant, neuromuscular blocking drug, inhalation anesthetic and the analgesic commonly used; But short and small operation need not used analgesic, cooperates low dose of antalgica as general anesthesia, has reduced the side effect that other analgesic using dosages bring.Suggestion uses target control pump or micro pump to carry out intravenous injection; Novel anesthesia agent of the present invention also can be diluted rear use, can only dilute with 5% glucose intravenous fluid, and dilution factor must not surpass 1: 5 (1.5mg/ml).Adult's dosage is 0.5～1.5mg/kg (induction period), and injection speed is controlled at 2mg/ second (induction period), 2～6mg/kg/h (maintenance phase); The pediatric pharmaceuticals amount is 1.0～2.0mg/kg (induction period), and injection speed is controlled at 2mg/ second (induction period), 5～8mg/kg/h (maintenance phase).

Example 2

A kind of Novel anesthesia agent mainly is comprised of propofol, also comprises Flos Daturae extract, Mentholum, camomile extract, Radix Notoginseng powder, Ramulus Cinnamomi powder and astragalus membranaceus powder, and concrete weight content proportioning is propofol 85%; Flos Daturae extract 8%; Mentholum 0.7%; Camomile extract 2.0%; Radix Notoginseng powder 2.0%; Astragalus membranaceus powder 2.3%.

Example 3

A kind of Novel anesthesia agent mainly is comprised of propofol, also comprises Flos Daturae extract, Mentholum, camomile extract, Radix Notoginseng powder, Ramulus Cinnamomi powder and astragalus membranaceus powder, and concrete weight content proportioning is propofol 90%; Flos Daturae extract 4%; Mentholum 0.7%; Camomile extract 1.5%; Radix Notoginseng powder 1.5%; Astragalus membranaceus powder 2.3%.

Flos Daturae extract, Mentholum, camomile extract, Radix Notoginseng powder and astragalus membranaceus powder are taken by weighing according to the prescription consumption, join in the propofol emulsion, mix and blend under 20～25 ℃ of temperature evenly mixes and leaves standstill, strict with after the national relevant specification processing again, use vial to store.

Claims

1. a Novel anesthesia agent mainly is comprised of propofol, it is characterized in that also comprising Flos Daturae extract, Mentholum, camomile extract, Radix Notoginseng powder and astragalus membranaceus powder, and concrete weight content proportioning is propofol 85～90%; Flos Daturae extract 4%～8%; Mentholum 0.5%～1%; Camomile extract 0.5%～2.5%; Radix Notoginseng powder 1%～3%; Astragalus membranaceus powder 1%～3%.

2. Novel anesthesia agent according to claim 1, it is characterized in that Flos Daturae extract, Mentholum, camomile extract, Radix Notoginseng powder and astragalus membranaceus powder according to prescription dosage, join in the propofol emulsion, mix and blend under 20～25 ℃ of temperature, evenly mix and leave standstill, use the 20ml vial to seal up for safekeeping.

3. Novel anesthesia agent according to claim 1, the dosage that it is characterized in that being grown up is 0.5～1.5mg/kg; The pediatric pharmaceuticals amount is 1.0～2.0mg/kg.